Skip to main content
main-content

The independent medical news service

20-09-2021 | Oncology | News | Article

STAMPEDE heralds ‘practice change’ for high-risk nonmetastatic prostate cancer

Supplementing androgen deprivation therapy with 2 years of an abiraterone acetate-based regimen significantly boosts the survival of men with high-risk nonmetastatic prostate cancer, show STAMPEDE results.

20-09-2021 | Oncology | News | Article

PEACE-1: Upfront triplet therapy gives OS advantage to men with mCSPC

The addition of abiraterone acetate to standard therapy with docetaxel plus androgen deprivation therapy significantly improves the overall survival of patients with de novo metastatic castration-sensitive prostate cancer, report the PEACE-1 investigators.

19-09-2021 | Oncology | News | Article

Trastuzumab deruxtecan supported for pretreated HER2-mutant NSCLC

Trastuzumab deruxtecan achieves durable responses in individuals who have received prior treatment for metastatic non-small-cell lung cancer harboring HER2 mutations, suggests the DESTINY-Lung01 trial.

19-09-2021 | Oncology | News | Article

ARCHES reports enzalutamide OS benefit in men with mCSPC

The final analysis of the ARCHES trial has demonstrated a significant overall survival boost with the addition of enzalutamide instead of placebo to androgen deprivation therapy in the metastatic castration-sensitive prostate cancer setting.

18-09-2021 | Oncology | News | Article

Trastuzumab deruxtecan shows ‘unprecedented efficacy’ in DESTINY-Breast03

Previously treated patients with HER2-positive metastatic breast cancer derive a significant progression-free survival benefit from trastuzumab deruxtecan relative to trastuzumab emtansine, find the DESTINY-Breast03 investigators.

18-09-2021 | Oncology | News | Article

COAST points to potential of durvalumab combinations in stage III NSCLC

Individuals with unresectable locally advanced non-small-cell lung cancer and no progression after chemoradiotherapy could benefit from the addition of the CD73 inhibitor oleclumab or the NKG2A-targeted agent monalizumab to consolidation durvalumab, suggest phase 2 results.

17-09-2021 | Oncology | News | Article

Cetrelimab–erdafitinib duo shows promise in advanced urothelial carcinoma

Adding the novel anti-PD-1 agent cetrelimab to the pan-FGFR inhibitor erdafitinib doubles the response rate in cisplatin-ineligible patients with untreated locally advanced or metastatic urothelial cancer and FGFR alterations, indicate trial data.

17-09-2021 | Oncology | News | Article

BrighTNess update confirms benefit of adding carboplatin to neoadjuvant chemo in TNBC

Adding carboplatin to neoadjuvant paclitaxel is sufficient to boost the outcomes of patients with triple-negative breast cancer, with no further improvement from the addition of veliparib to the dual regimen, confirms a follow-up analysis of the BrighTNess trial.

17-09-2021 | Oncology | News | Article

Updated CheckMate 743 data support dual checkpoint blockade in mesothelioma

Extended follow-up of the phase 3 CheckMate 743 trial shows the continued overall survival benefit of first-line treatment with nivolumab plus ipilimumab over chemotherapy in patients with unresectable malignant pleural mesothelioma.

17-09-2021 | Oncology | News | Article

FDA approves mobocertinib for advanced NSCLC with EGFR exon 20 insertions

Click through to read more about this approval

16-09-2021 | Oncology | News | Article

Residual cancer burden may predict treatment efficacy in breast cancer

Residual cancer burden offers prognostic information after neoadjuvant chemotherapy across breast cancer subtypes and treatments, show data from I-SPY2.

15-09-2021 | Oncology | News | Article

No overall survival benefit with first-line bevacizumab–erlotinib in EGFR-mutant NSCLC

The addition of bevacizumab to erlotinib does not improve the overall survival of treatment-naïve patients with advanced non-small-cell lung cancer harboring an activating EGFR mutation, NEJ026 study data show.

14-09-2021 | Oncology | News | Article

No new safety signals for neoadjuvant, maintenance atezolizumab in mesothelioma

Neoadjuvant atezolizumab meets researcher-defined safety criteria for use in combination with cisplatin plus pemetrexed and then as postsurgical maintenance therapy for people with resectable malignant pleural mesothelioma.

14-09-2021 | Oncology | News | Article

Flexibility positively impacts lung cancer clinical trial participation in COVID-19 era

Strategies to improve flexibility in clinical trials may improve enrollment rates during and after the COVID-19 pandemic, according to a study presented at the IASLC 2021 World Conference on Lung Cancer.

13-09-2021 | Oncology | News | Article

​​​​​​​Pretreatment ctDNA levels may predict survival in neoadjuvant-treated NSCLC patients

Assessing circulating tumor DNA levels prior to initiating neoadjuvant chemoimmunotherapy for locally advanced non-small-cell lung cancer could help to identify patients likely to derive long-term benefit from treatment, suggest exploratory data.

13-09-2021 | Oncology | News | Article

Atezolizumab plus chemotherapy feasible for NSCLC with brain metastases

Treatment with carboplatin and pemetrexed plus atezolizumab shows promise for people with nonsquamous non-small-cell lung cancer and asymptomatic, untreated brain metastases, phase 2 study findings indicate.

10-09-2021 | Oncology | News | Article

No OS benefit of lurbinectedin plus doxorubicin in relapsed SCLC

The ATLANTIS trial has found no significant overall survival improvement with the combination of lurbinectedin and doxorubicin versus chemotherapy in previously treated patients with small-cell lung cancer.

10-09-2021 | Oncology | News | Article

Surgery extent impacts long-term QoL in young breast cancer survivors

Young women who undergo mastectomy for breast cancer report poorer quality of life than those treated with breast conserving therapy more than 5 years after surgery, particularly when they also receive radiotherapy, research shows.

09-09-2021 | Oncology | News | Article

Durvalumab–tremelimumab plus chemo ‘a potential new first-line option’ for metastatic NSCLC

The addition of durvalumab plus tremelimumab to chemotherapy significantly improves the outcomes of people with untreated metastatic non-small-cell lung cancer, shows the POSEIDON trial.

08-09-2021 | Oncology | Highlight | Article

PRONOUCE fails to resolve CV safety questions for GnRH antagonists, agonists

Slow recruitment and low event rates have led to early termination of the PRONOUNCE trial, which hoped to determine the relative cardiovascular safety of gonadotropin-releasing hormone antagonists and agonists in men with prostate cancer.

Image Credits